DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG

H3 K27M-mutant gliomas often manifest as midline gliomas, have a dismal prognosis, and have no effective treatments. ONC201 efficacy has been shown in high-grade glioma preclinical models and durable responses with single agent ONC201 have been reported in adults with recurrent H3 K27M-mutant glioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, Sharon, Tarapore, Rohinton, Allen, Jeffrey, Zaky, Wafik, Odia, Yazmin, Hall, Matthew, Daghistani, Doured, Khatib, Ziad, Koschmann, Carl, Aguilera, Dolly, MacDonald, Tobey, Fouladi, Maryam, McGovern, Susan, Kline, Cassie, Vitanza, Nicholas, Lu, Guangrong, Merdinger, Krystal, Oster, Wolfgang, Allen, Joshua, Khatua, Soumen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Diffuse Midline Glioma/DIPG
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715960/
http://dx.doi.org/10.1093/neuonc/noaa222.097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715960/
http://dx.doi.org/10.1093/neuonc/noaa222.097

Ejemplares similares